3 Stocks Boosting The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.5%) at 16,791 as of Thursday, June 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,231 issues advancing vs. 1,744 declining with 167 unchanged.

The Health Care sector currently sits down 0.4% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Vertex Pharmaceuticals ( VRTX), up 1.9%, and Shire ( SHPG), up 0.6%. On the negative front, top decliners within the sector include Intercept Pharmaceuticals ( ICPT), down 4.6%, Community Health Systems ( CYH), down 3.8%, Universal Health Services ( UHS), down 3.7%, HCA Holdings ( HCA), down 2.3% and Grifols ( GRFS), down 1.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.90 (2.8%) to $33.19 on average volume. Thus far, 73,222 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 135,900 shares. The stock has ranged in price between $33.08-$33.28 after having opened the day at $33.19 as compared to the previous trading day's close of $32.29.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. Fresenius Medical Care AG & Co. KGaA has a market cap of $19.3 billion and is part of the health services industry. Shares are down 9.2% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and weak operating cash flow. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Taro Pharmaceutical Industries ( TARO) is up $4.46 (3.9%) to $118.38 on heavy volume. Thus far, 72,532 shares of Taro Pharmaceutical Industries exchanged hands as compared to its average daily volume of 51,200 shares. The stock has ranged in price between $113.23-$118.38 after having opened the day at $113.23 as compared to the previous trading day's close of $113.92.

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, together with its subsidiaries, engages in the research, development, production, and marketing of pharmaceutical products primarily in the United States, Canada, and Israel. Taro Pharmaceutical Industries has a market cap of $5.0 billion and is part of the drugs industry. Shares are up 15.2% year-to-date as of the close of trading on Wednesday.

TheStreet Ratings rates Taro Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Taro Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $0.84 (1.5%) to $55.84 on average volume. Thus far, 4.2 million shares of AbbVie exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $54.97-$55.92 after having opened the day at $55.07 as compared to the previous trading day's close of $55.00.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $85.2 billion and is part of the drugs industry. Shares are up 4.2% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate AbbVie a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing